About us

About N-Gene Research Laboratories

N-Gene Inc. was founded in 1997 for developing a family of proprietary, small molecules to address a wide range of adverse medical conditions. The lead molecule of the company’s late-stage portfolio – BGP-15 – was initially developed for insulin resistance and reached phase 2 human clinical stage.

Recent pre-clinical studies and findings of complex and diverse mode-of-action suggest that BGP-15 is an ideal candidate for a diverse orphan portfolio. To exploit these new findings N-Gene has signed a licensing agreement with Mitochon Technologies and Vudbenk Life Science, which companies are continuing BGP-15’s orphan development.

N-Gene Research Laboratories is developing small molecule-based therapeutics for the treatment of diabetes. The company's lead product candidate BGP-15 restores nitric oxide synthase and inducible heat shock protein expression resulting in correction of damaged mitochondrial and endoplasmic reticulum functions and improved mitochondrial biogenesis. These in turn help in increasing insulin sensitivity. The product has completed Phase 2a clinical trials. The company has also developed another skincare product BGP-15M which has also completed Phase 2 clinical trials.